SPANISH ASSOCIATION OF ATAXIA PATIENTS FEDAES  In 1998, we generated the e-mailing list of Hispataxia and the webpage.  In 2000, we contacted researchers.

Slides:



Advertisements
Similar presentations
EUROPEAN COMMISSION Community health programmes: first results and future challenges for the EU regions Donata Meroni European Commission - DG Health and.
Advertisements

¨ Dr Alain Garcia General Secretary of the Rare Diseases National Plan The second National Plan for Rare Diseases in France
7 th Framework Programme (FP7) - Malta’s participation th January 2013 Anthea Fabri FP7 National Coordinator Malta Council for Science and.
AVV February 2005 Support of the European Union to Research on Rare Diseases Dr Alain Vanvossel European Commission Research Directorate General Health.
Research & Innovation Evolution from IMI1 to IMI2: challenges ahead Elmar Nimmesgern, PhD DG Research & Innovation 1.
KOSICE September KOURIR association KOSICE September The KOURIR association  Presentation of KOURIR  Objectives n Information - Communication.
Eurordis.org EURORDIS – hvad går det ud på? v. Birthe Byskov Holm, formand Sjældne Diagnoser 1.
The copyright © is owned by the author of this document. Please do not duplicate. Disclaimer: the „Fit for Health project partners.
Innovative Medicines Initiative - IMI
Networking with Southeast Europe SEE-ERA.NET Pilot Joint Call for Research Proposals Southeast European Era-Net.
Research & Innovation International Rare Disease Consortium: Data Sharing Policy 3 rd International Traumatic Brain Injury Research Meeting Catherine BERENS.
Rare Diseases Foundation Céline Hubert Pr Nicolas Lévy
Translation of Stem Cells therapies: How to Balance Hope and Uncertainties? E. Rial-Sebbag and A. Blasimme.
The SEE-ERA.NET project - a brief overview on the interim project results.
Estonian experience in Horizon 2020 Ülle Must
European Health Forum Gastein, Bad Hofgastein, Austria, September 2002 Towards the Sixth Framework Programme Parallel Forum V 26 September 2002 Public.
Science, research and developmentEuropean Commission Chile-EC S&T Agreement Brussels, 24 September 2002 Life Sciences, Genomics and Biotechnology for Health.
121 Intramural Biomedical Projects in Rare Diseases (PIBER) Support Platforms for Research into Rare Diseases (PITER) Management Office Scientific Director.
Presidency of Council of Ministers National Committee for Biosafety, Biotechnology and Life Sciences (D.P.C.M. March 19, 2007)
Activity Report for /11/ During last year, it was stated that: There had been a strong effort of the president, Dr Gérard Nguyen,
European Clinical Trial Directive (Directive 2001/20/EC) dr. Cees Smit (NPCF/EGAN) EPF Annual Meeting May 19, Brussels.
Friedreich Ataxia Friedreich Ataxia Research Association Australasia.
Dr Stewart Hay, CEO | | (03) www.therapeuticinnovation.com.au.
SEE-ERA.NET Initiatives Pilot Joint Call for Research Proposals IGLO Open Session, Southeast European Era-Net Florian Gruber, Dissemination and.
BioSciencs Foro November 8th, New York Joaquin Guinea Chairman of BIOMADRID (
Dr. José M. Millán, PhD Deputy Director of CIBERER Universitary Hospital La Fe, Valencia, Spain Barriers and Challenges in Rare Diseases Research Centre.
PULMAN-XT PROJECT and ITS EFFECTS ON TURKISH LIBRARIANSHIP Assoc. Prof. Dr. Bulent YILMAZ and Didar BAYIR PROJECT COORDINATORS, TURKEY.
UHH 1 AARHUS UNIVERSITY RESEARCH MANAGEMENT AND RESEARCH SUPPORT.
EPOS Preparatory phase Torild van Eck (ORFEUS) Call INFRA Deadline: December 3, 2009 Funding: between 3 and 6 MEuro Duration: max 4 year.
The Concept of the European Platform of Women Scientists An instrument of support and a way to become active in the policy debate Isabel Beuter, M.A. Center.
Telematikplattform für Medizinische Forschungsnetze (TMF) e.V. TMF – A Common Platform for Medical Research Networks in Germany Improving the Organisation.
EFHSP First things first. Rare!Together PRO’s Contact between people from different countries and various cultural backgrounds sharing the same special.
September 13, 2007SGH&M2B International&Training Workshop What does the European Technology Platform “Innovative Medicines initiative” offer? Vitalijs.
ResearchEuropean Commission FP 6 - Thematic Priority 1 International co-operation.
Orphanet Europe State of the Art of Database and Services Polish activity Orphanet Europe State of the Art of Database and Services Polish.
The Maruzza Lefebvre D’Ovidio Foundation Silvia Lefebvre D’Ovidio.
FET-EEU Project - Warsaw 13 th June 2005 ADEME – FG/CP ADEME Agence de l’Environnement et de la Maîtrise de l’Energie FRANCE FET – EEU Project Kick-off.
PROPOSAL for the establishment of the ENGINE (European Network for Green Infrastructure KNowledge and Experience) Eleftherios Loizou Managing Director.
American Society for Clinical Laboratory Science What Your Professional Society Can Do For You!
Embedding Science and Society in FP-6 Brussels, CCAB, October 2002.
EURORDIS Eurordis Position on Research Priorities for Rare Diseases.
COST European COoperation in Science and Technology COST European COoperation in Science and Technology Belspo, 14 March 2014 Benjamin MONNOYE, Attaché.
“IP Universities” Istanbul, May 16 to 18, 2012 Albert Long Hall, BOGAZICI UNIVERSITY Mr. Pedro Cartagena Technical Adviser SPTO. Madrid, Spain.
The promotion of epilepsy research in Europe Janet Mifsud, Reetta Kalviainen.
The ERA-NET TRANSCAN-2, in continuity with the preceding ERA-NET TRANSCAN, aims at linking translational cancer research funding programmes in 15 Member.
Human Embryos and Gene-editing Research and regulation in China Prof. Zhihong Xu, Peking University & Chinese Academy of Sciences.
SARC Individual and Institutional Participation 2013.
EHFG 7 October 2005 – Patient Safety & Research UK Presidency Workshop on Patient Safety, EHFG, Bad Hofgastein,7 September 2005 Kevin McCarthy, European.
The 7th Framework Programme for Research: Strategy of international cooperation activities Robert Burmanjer Head of Unit, “International Scientific Cooperation.
European Commission Virtual Institutes Workshop--28 September Thematic network contracts Megan Richards DG RTD Virtual Institutes  Thematic Network.
Research and Innovation Research and Innovation Promoting health research and innovation in Horizon 2020 Research and Innovation Research and Innovation.
© UEG Presentation by Towards more coordination in health research: a report on the UEG research symposium 16/11/2012 Michael Manns General Assembly.
Towards Gendered Science and Research: Gender Mainstreaming in the EU Science Policies Alexandra Bitusikova 7 September 2005 Bratislava, Slovakia.
Annual National Health Research Forum Ministry of Health 14 March 2013.
PLANET & RNPST INDUSTRIAL DAY Bilbao, 24 October 2003 Luis Castillo PLANET RNPSTIKERLANUNIVERSITY CARLOS III MADRID UNIVERSITY OF GRANADA.
EUPATI Training Course Patient Experts in Medicines Research & Development The project is receiving support from the Innovative Medicines Initiative Joint.
European Patients’ Academy on Therapeutic Innovation – The project is receiving support from the.
Designation process of the Collaborating Centre BCN WHO-FIC Network Agency for Health Quality and Assessment of Catalonia October 2014.
Second Meeting of the Evaluation Expert Committee 23 June 2009 Elisenda Ruiz de Villalobos Zabala Ministry of Environment and Rural and Marine Affairs.
«Patients’ rights have no borders»
Update of the Scientific Secretariat
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
EU-Russia Cooperation in the Areas of Science, Research and Innovation
A Centre for New Methods in Computational Diagnostics and Personalised Therapy This EU H2020 ‘Teaming for Excellence’ project develops a Business Case.
European Environment Agency
Setting up an ERIC 11 May 2012 Richard Derksen
HPH Strategy Seminar Beijing, China 7 september 2013 Andrea Limbourg
European Innovation Platform for Knowledge Intensive Services Elke Van Tendeloo DG Enterprise and Industry Brussels, 04 June 2007.
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Friedreich’s Ataxia.
Presentation transcript:

SPANISH ASSOCIATION OF ATAXIA PATIENTS FEDAES  In 1998, we generated the ing list of Hispataxia and the webpage.  In 2000, we contacted researchers in Spain and abroad interested in ataxia research.  In 2001, the Spanish Association of ataxia patients FEDAES was established from the ing list Hispataxia.  FEDAES is included in EUROATAXIA, FEDER and EURORDIS.  Goals: promote ataxia research and improve the life quality of patients with ataxia.

ACTIVITIES SUPPORTING RESEARCH (I)  Steps for fabricating and obtaining recombinant IGF1 and established a clinical assay with IGF1 (La Paz Hospital, Madrid).  Contribution with patients to clinical trials with idebenone.  Elaboration and publication of booklets disseminating clinical and scientific information to patients.  Provide information about public and private research calls to scientists.

 Support to scientists working on ataxias in Spain and abroad in order to obtain funding from public and private agencies: Spanish Ministry of Health, Spanish Ministry of Science and Innovation, ICO Funds, La Caixa, European Commission (FP6: EUROSCA, and FP7), etc.  Support to scientists using innovative therapeutic approaches such as gene and cellular therapies.  Support to clinical researchers working on different aspects of ataxia: clinical trials, genetics, physiotherapy, psychology, etc. ACTIVITIES SUPPORTING RESEARCH (II)

 We strongly support research with embryonic and somatic stem cells in Spain.  We promote research with the following drugs: Idebenone Growth Hormone Riboflavine Deferriprone EPO IGF1 Phosphatil-B (multivitaminic and phospholipidis complex) ACTIVITIES SUPPORTING RESEARCH (III)

 On several occasions, we have proposed candidates of Spanish researchers to different awards such as Lilly Foundation, Prince Felipe, Queen Sophia, March Foundation, Albert Sols, etc.  Contributions to several regulatory and technical documents such as the Modelo sociosanitario español, Ley de calidad, Cartera de servicios del SNS.  Active members of the Ethical Committee of the Institute for Rare Disorders. ACTIVITIES SUPPORTING RESEARCH (IV)

ACTIVITIES SUPPORTING RESEARCH (V)  Active members of Board of Directors of FEDER contributing to the elaboration of Spanish and European regulatory and technical documents.  Participation in the elaboration of the Spanish National Plan of Rare Disorders. Coordination of the groups working on therapies for Rare Diseases.

 Organisation of Meetings for Clinical and Basic Researchers: January Gregorio Marañón Hospital, Madrid. June La Paz Hospital, Madrid. May National School of Health, Madrid.  Organisation of Annual Workshops (Jornadas) with patients and scientists. ACTIVITIES SUPPORTING RESEARCH (VI)

About FP7:  First meeting in Hospital La Paz, Madrid. May  The first call explicitly excludes funding of rare neurological disorders. So in order to lobby ataxia research: Meeting with Octavi Quintana DG of Health, EC. Letters from Euroataxia members to members of European Parliament and Technicians elaborating proposals for FP7. Meetings where Spain elaborates proposals. Spain proposed to include funding for neurological rare diseases in FP7. Funding for neurological rare diseases is approved by the EC. We will support, alone or in collaboration with other European ataxia patient Associations, the ataxia network and ataxia research in FP7. ACTIVITIES SUPPORTING RESEARCH (VII)

 We have provided with funds support to: Obtaining recombinant IGF1 Ataxia research in Gregorio Marañón Hospital, Madrid. Ataxia research in La Paz Hospital, Madrid. Ataxia research in CBM-CSIC, Madrid. Ataxia research on TAT-frataxin.  More calls to fund projects in a near future, depending on budget. ACTIVITIES SUPPORTING RESEARCH (VIII)

Our work to disseminate ataxia  Through our webpage.  Through our monthly newsletters.  By and communications of all types.  By participating in National and International meetings and being active members of Associations.  By organising meetings on ataxias y promoting National and Europeans (FP7) research networks.  Visiting Research Centres and Hospitals.  Promoting and Lobbying funding excellent research on ataxia in Spain and Europe.

 Organisation of the next EuroATAXIA General meeting in BARCELONA, SPAIN! September 2009 You are all invited!!!! Our work to disseminate ataxia

Many thanks to:  Miguel Angel Cibrián, President of FEDAES.  All friends forming the Spanish Ataxia Association FEDAES.  Dr. Antoni Matilla-Dueñas, for translating these slides and his collaboration and friendship during all these years.  To all of you for attending this lecture in Spanish, and for your dedication to ataxia research. Be welcome and thank you!